The Women In Bio (WIB) Washington DC/Baltimore Chapter and Association for Women in Science (AWIS) Bethesda Chapter invite you to a networking happy hour at La Tasca, Rockville, MD. Don’t miss the opportunity to meet and connect with industry professionals, entrepreneurs, and researchers, while enjoying sangrias and tapas at the lounge. This event is open to both members and non-members.
All guests will enjoy complimentary appetizers and two drink tickets
Submit your nominations for the Verl Zanders Emerging Business of the Year! Nominate your choice for an emerging company that is leading innovation in Metro-Maryland.
Nomination Deadline: Friday, August 26, 2016
EU and US strengthen their collaboration on eHealth IT
In December 2010, the US Department of Health and Human Services (HHS) and the European Commission’s DG CONNECT signed a Memorandum of UnderstandingWeb Site Disclaimers (MoU) for transatlantic Cooperation on eHealth/Health IT.
In the spring of 2013, DG CONNECT and HHS published a first Roadmap of MoU actionsWeb Site Disclaimers, focusing on two priority areas (work-streams):
Help MdBio Foundation kick off the school year with an ice cream cone and tour of MdBioLab. Tour the lab, meet the team or just eat your ice cream. Doors open 12 – 3PM.
August 31, 2016 | 12PM – 3PM | JHU MoCo Parking Lot
The Tech Council of Maryland is pleased to announce that Martin “Marty” Rosendale has been appointed as senior executive advisor. In this role, he will assist the association and board of directors in fulfilling its strategic plan objectives.
Marty is a member of the Tech Council and is CEO of Selnova LLC, an advisory firm founded to help entrepreneurs navigate critical and challenging company transitions. He is also a founding member of the managing committee that established and oversees TCM’s Venture Mentoring Service, where he and other TCM members act as mentors and provide their expertise to promising Maryland tech and life sciences companies that are preparing for an initial venture or institutional financing event.
If immunotherapy has the cancer community riveted on the treatment side, liquid biopsies are equally exciting on the diagnostics end. And IBM is bringing its research heft to bear on the world of liquid biopsy with an intent to build a lab-on-a-chip technology that can separate particles at the nanoscale.
Montgomery County Executive Ike Leggett is asking the business community to provide feedback on County services by completing an online Business Survey.
Mr. Leggett has kicked off the Excellence in Business Services initiative, continuing his efforts to make it easier for businesses to start, grow and thrive in Montgomery County. This business survey is designed to help the county identify areas of improvement in its interactions with business.
Business vitality is critical to a healthy economy that supports the quality of life we all enjoy and Montgomery County is committed to ensuring that businesses have a positive experience when interacting with the County.
Businesses also are welcome to contact the project lead directly with thoughts and feedback: Judy Stephenson judy.stephenson@montgomerycountymd.gov
August 1, 2016: All Points, Maryland – Today Startup Maryland announced dates (September 10 – October 8) and the rough route for the STRT1UP Road Show, the fifth annual state-wide tour and celebration of entrepreneurship and high-growth innovation-centric startup companies.
Roche ($ROG) and Inovio Pharmaceuticals ($INO) had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that dream is officially dead as Roche has returned the second of two candidates and discontinued its partnership with Inovio.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Method of Achieving a Thymosin Beta 4 Concentration in a Human Patient. The patent covers treating a patient with a desired concentration of Thymosin Beta 4 (Tβ4) over a period of time, as well as treating a patient by maintaining a desired concentration of Tβ4 in a pharmacologically effective range. The patent expiry will be in late 2031, or longer depending on any extensions available from the USPTO.
